Hu B, et al. - Researchers analyzed data from all relevant articles assessing the prognostic value in cancer patients of DEP domain containing mammalian target of rapamycin (mTOR)-interacting protein (DEPTOR), a recently discovered endogenous inhibitor of mTOR. They performed meta-analysis including nine eligible studies with 974 cancer patients. No association of DEPTOR expression with the overall survival and event-free survival was found in cancer patients. Expression level of DEPTOR also did not significantly correlate with clinicopathological characteristics, such as tumor stage, lymph node metastasis, differentiation grade and gender. In cancer patients, DEPTOR could be overexpressed or downregulated, but that did not translate to it being a potential marker that could predict outcomes.